GRI Index

GRI Content Index for Biogen’s 2018 Corporate Social Responsibility Report

GRI Indicator	Description	Reference	SDG Alignment*
GRI 102: GENERAL DISCLOSURES 2016
Organizational Profile
102-1	Name of the organization	Biogen Inc.
102-2	Activities, brands, products, and services	CEO Statement – 2018 Annual Report Item 1., Business, 2018 Form 10-K, page 1
102-3	Location of headquarters	Corporate Headquarters: Cambridge, Massachusetts (U.S.)
102-4	Location of operations	Pharmaceutical Operations & Technology Item 2., Properties, 2018 Form 10-K, pages 47-48
102-5	Ownership and legal form	Corporate and Stockholder Information – 2018 Annual Report
102-6	Markets served	Item 1., Business, 2018 Form 10-K, pages 10-12
102-7	Scale of the organization	Highlights – 2018 Annual Report Item 1., Business, 2018 Form 10-K Item 6., Selected Financial Data, 2018 Form 10-K, pages 51-53
102-8	Information on employees and other workers	Item 1., Business, 2018 Form 10-K, pages 30-31
102-9	Supply chain	Item 1., Business, 2018 Form 10-K, pages 28-29	Goal 12
102-10	Significant changes to the organization and its supply chain	Item 1., Business, 2018 Form 10-K, pages 2-3
102-11	Precautionary Principle or approach	Biogen applies the precautionary approach by achieving carbon neutrality, ensuring the safety of patients, and performing detailed risk analyses related to our operations.
102-12	External initiatives	Our Guiding Principles Advocacy Engagement Environment – 2018 Corporate Social Responsibility Report
102-13	Membership of associations	Environment – 2018 Corporate Social Responsibility Report Biogen membership associations: RE100 Company – Global initiative uniting more than 100 influential businesses committed to 100% renewable electricity Pharmaceutical Supply Chain Initiative (PSCI) – Organization of leading global pharmaceutical companies focused on increasing the capabilities and responsibility of our supply chains Pharmaceutical Product Stewardship Work Group – Association for drug and sharp manufacturers and marketers formed to address the disposal of unused and unwanted pharmaceutical products.
Strategy
102-14	Statement from senior decision-maker	CEO Letter – 2018 Annual Report CEO Statement – 2018 Corporate Social Responsibility Report
102-15	Key impacts, risks, and opportunities	Item 1A., Risk Factors, 2018 Form 10-K, pages 34-47
Ethics and Integrity
102-16	Values, principles, standards, and norms of behavior	Code of Business Conduct (Values in Action) Our Guiding Principles
102-18	Governance structure	Executive Committee – 2018 Annual Report Board of Directors Executive Leadership
Stakeholder Engagement
102-40	List of stakeholder groups	GRI Materiality Assessment
102-41	Collective bargaining agreements	Approximately 5.3 percent of our employees are under a collective bargaining agreement. All of these employees work in our Hillerød, Denmark, manufacturing facility.
102-42	Identifying and selecting stakeholders	GRI Materiality Assessment
102-43	Approach to stakeholder engagement	GRI Materiality Assessment
102-44	Key topics and concerns raised	GRI Materiality Assessment
Reporting Practice
102-45	Entities included in the consolidated financial statements	All major entities are included in the boundaries of this report. See the 2018 Form 10-K
102-46	Defining report content and topic Boundaries	GRI Materiality Assessment
102-47	List of material topics	GRI Materiality Assessment
102-48	Restatements of information	No restatements were made
102-49	Changes in reporting	No significant changes from the previous reporting period
102-50	Reporting period	Data covers fiscal year 2018; ending December 31, 2018. Some activities from 2019 are also included
102-51	Date of most recent report	April 30, 2019
102-52	Reporting cycle	We report on an annual basis
102-53	Contact point for questions regarding the report	Corporate Social Responsibility contact: public.affairs@biogen.com
102-54	Claims of reporting in accordance with the GRI Standards	This report has been prepared in accordance with the GRI Standards: Core option
102-55	GRI content index	GRI Index
102-56	External assurance	ERM CVS Independent Assurance Statement to Biogen Inc.
GRI 103: TOPICS AND TOPIC BOUNDARIES
103-1	Explanation of the material topic and its Boundary	GRI Report GRI Materiality Process
103-2	The management approach and its components	Strategy – 2018 Annual Report 2018 Corporate Social Responsibility Report
103-3	Evaluation of the management approach	Consolidated Financial Statements, 2018 Form 10-K, pages F-83-84 2018 Corporate Social Responsibility Report
GRI 200-400: TOPIC-SPECIFIC DISCLOSURES 2016
Economic
Economic Performance
201-1	Direct economic value generated and distributed	GAAP to Non-GAAP Reconciliation – 2018 Annual Report Item 6., Selected Financial Data, 2018 Form 10-K, pages 51, F-78
201-2	Financial implications and other risks and opportunities due to climate change	Environment – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure Item 1A., Risk Factors, 2018 Form 10-K, page 40
201-3	Defined benefit plan obligations and other retirement plans	Consolidated Financial Statements, 2018 Form 10-K, page F-78
Indirect Economic Impacts
203-2	Significant indirect economic impacts	2018 Corporate Social Responsibility Report GRI Materiality Assessment	Goal 3 Goal 4 Goal 8
Procurement Practices
204-1	Proportion of spending on local suppliers	Not applicable Biogen discloses this information only on a global level Our Guiding Principles Supplier Diversity – Working With Us	Goal 5 Goal 8
Environment
Water and Effluents
303-1	Interactions with water as a shared resource	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 6
303-3	Water withdrawal	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 6
303-4	Water discharge	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 6
303-5	Water consumption	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 6
Emissions
305-1	Direct (Scope 1) GHG emissions	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 7 Goal 13
305-2	Energy indirect (Scope 2) GHG emissions	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 7 Goal 13
305-3	Other indirect (Scope 3) GHG emissions	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 7 Goal 13
305-5	Reduction of GHG emissions	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Carbon Disclosure Project (CDP) Disclosure	Goal 7 Goal 13
Effluents and Waste
306-2	Waste by type and disposal method	Environment – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report	Goal 12
Environmental Compliance
307-1	Non-compliance with environmental laws and regulations	There were no significant instances of non-compliance in 2018 Our Guiding Principles Item 1A., Risk Factors, 2018 Form 10-K, page 46	Goal 12
Supplier Environmental Assessments
308-1	New suppliers that were screened using environmental criteria	Environment – 2018 Corporate Social Responsibility Report 2018 Supplier Environment & Social Assessments	Goal 12
308-2	Negative environmental impacts in the supply chain and actions taken	Environment – 2018 Corporate Social Responsibility Report 2018 Supplier Environment & Social Assessments Item 1A., Risk Factors, 2018 Form 10-K, page 46	Goal 12
Social
Employment
401-1	New employee hires and employee turnover	Confidentiality constraints Break down by age group, gender is not shared publicly.
Occupational Health and Safety
403-1	Occupational health and safety management system	Employees – 2018 Corporate Social Responsibility Report Environmental, Health and Safety Policy Statement	Goal 3 Goal 8
403-2	Hazard identification, risk assessment, and incident investigation	Employees – 2018 Corporate Social Responsibility Report Environmental, Health and Safety Policy Statement	Goal 3 Goal 8
403-4	Worker participation, consultation, and communication on occupational health and safety	Employees – 2018 Corporate Social Responsibility Report Environmental, Health and Safety Policy Statement	Goal 3 Goal 8
403-9	Work-related injuries	Employees – 2018 Corporate Social Responsibility Report GRI Table – 2018 Corporate Social Responsibility Report Environmental, Health and Safety Policy Statement	Goal 3 Goal 8
Diversity and Equal Opportunity
405-1	Diversity of governance bodies and employees	Employees – 2018 Corporate Social Responsibility Report Board of Directors	Goal 5
405-2	Ratio of basic salary and remuneration of women to men	Confidentiality constraints Biogen does not disclose externally any salary and wages related data except the Executive Compensation of the Executive Committee and Board of Directors
Local Communities
413-1	Operations with local community engagement, impact assessments, and development programs	Community – 2018 Corporate Social Responsibility Report Culture & Engagement – 2018 Annual Report Corporate Giving	Goal 3 Goal 4
Supplier Social Assessment
414-1	New suppliers that were screened using social criteria	Employees – 2018 Corporate Social Responsibility Report Supplier Diversity – Working With Us Code of Business Conduct (Values in Action) 2018 Supplier Environment & Social Assessments	Goal 5 Goal 8 Goal 12
414-2	Negative social impacts in the supply chain and actions taken	Employees – 2018 Corporate Social Responsibility Report Supplier Diversity – Working With Us Code of Business Conduct (Values in Action) 2018 Supplier Environment & Social Assessments	Goal 5 Goal 8 Goal 12
Public Policy
415-1	Political contributions	Our Guiding Principles Political Contributions Policy 2018 Form 10-K	Goal 16
Customer Health and Safety
416-1	Assessment of the health and safety impacts of product and service categories	Patients – 2018 Corporate Social Responsibility Report Products & Pipeline – 2018 Annual Report Our Guiding Principles Patient Safety Product Stewardship	Goal 3
416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	There were no significant instances of non-compliance in 2018 Products & Pipeline – 2018 Annual Report Patient Safety Product Stewardship	Goal 3
Marketing and Labeling
417-1	Requirements for product and service information and labeling	Our Guiding Principles Patient Safety Product Stewardship	Goal 3
417-2	Incidents of non-compliance concerning product and service information and labeling	There were no significant instances of non-compliance in 2018 Our Guiding Principles	Goal 3
417-3	Incidents of non-compliance concerning marketing communications	There were no significant instances of non-compliance in 2018 Our Guiding Principles	Goal 3
Customer Privacy
418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	There were no significant instances of breaches of customer privacy or losses of customer data in 2018 Our Guiding Principles Global Privacy Program	Goal 16

GRI Content Index for Biogen’s 2018 Corporate Social Responsibility Report

Organizational Profile

102-1

Name of the organization

102-2

Activities, brands, products, and services

102-3

Location of headquarters

Corporate Headquarters: Cambridge, Massachusetts (U.S.)

102-4

Location of operations

102-5

Ownership and legal form

102-6

Markets served

102-7

Scale of the organization

102-8

Information on employees and other workers

102-9

Supply chain

Goal 12

102-10

Significant changes to the organization and its supply chain

102-11

Precautionary Principle or approach

Biogen applies the precautionary approach by achieving carbon neutrality, ensuring the safety of patients, and performing detailed risk analyses related to our operations.

102-12

External initiatives

102-13

Membership of associations

Biogen membership associations:

RE100 Company – Global initiative uniting more than 100 influential businesses committed to 100% renewable electricity

Pharmaceutical Supply Chain Initiative (PSCI) – Organization of leading global pharmaceutical companies focused on increasing the capabilities and responsibility of our supply chains

Pharmaceutical Product Stewardship Work Group – Association for drug and sharp manufacturers and marketers formed to address the disposal of unused and unwanted pharmaceutical products.

Strategy

102-14

Statement from senior decision-maker

102-15

Key impacts, risks, and opportunities

Ethics and Integrity

102-16

Values, principles, standards, and norms of behavior

102-18

Governance structure

Stakeholder Engagement

102-40

List of stakeholder groups

102-41

Collective bargaining agreements

Approximately 5.3 percent of our employees are under a collective bargaining agreement. All of these employees work in our Hillerød, Denmark, manufacturing facility.

102-42

Identifying and selecting stakeholders

102-43

Approach to stakeholder engagement

102-44

Key topics and concerns raised

Reporting Practice

102-45

Entities included in the consolidated financial statements

All major entities are included in the boundaries of this report. See the 2018 Form 10-K

102-46

Defining report content and topic Boundaries

102-47

List of material topics

102-48

Restatements of information

No restatements were made

102-49

Changes in reporting

No significant changes from the previous reporting period

102-50

Reporting period

Data covers fiscal year 2018; ending December 31, 2018. Some activities from 2019 are also included

102-51

Date of most recent report

April 30, 2019

102-52

Reporting cycle

We report on an annual basis